Top

Published in:

01-09-2017 | Review Article

Role of TIM-3 in ovarian cancer

Authors: Y. Xu, H. Zhang, Y. Huang, X. Rui, F. Zheng

Published in: Clinical and Translational Oncology | Issue 9/2017

Abstract

Evidences have suggested that immunotherapy for ovarian cancer is effective. Immune checkpoints have emerged in the field of cancer immunotherapy. Multiple studies have shown negative regulation of TIM-3 expression on CD4⁺ and CD8⁺ T cells and other immunocytes. Overexpression of TIM-3 in innate immune cells has been found in certain types of tumor. The blockade of TIM-3 leads to sustained anti-tumor reactions. TIM-3 plays an inhibitive role for immunity in ovarian cancer. TIM-3 is involved in the development of various subtypes of ovarian cancer and thus has the potential to be a therapeutic target for treatment of ovarian cancer.

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. Cancer J Clin. 2016. doi:10.3322/caac.21338.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.CrossRef

Houben E, van Haalen HG, Sparreboom W, Overbeek JA, Ezendam NP, Pijnenborg JM, et al. Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes. Med Oncol. 2017;34(4):50. doi:10.1007/s12032-017-0901-x.CrossRefPubMed

Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, et al. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther. 2010;10(1):47–60. doi:10.1586/era.09.167.CrossRefPubMed

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. New Eng J Med. 2013;369(2):122–33. doi:10.1056/NEJMoa1302369.CrossRefPubMed

Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev. 2011;241(1):180–205. doi:10.1111/j.1600-065X.2011.01011.x.CrossRefPubMedPubMedCentral

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239.CrossRefPubMedPubMedCentral

Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.CrossRefPubMed

da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014;2(5):410–22. doi:10.1158/2326-6066.CIR-13-0171.CrossRefPubMedPubMedCentral

10.

Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-Targeted Antitumor Immunotherapy. Can Res. 2011;71(21):6567–71. doi:10.1158/0008-5472.CAN-11-1487.CrossRef

11.

Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, et al. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol. 2007;127(4):906–14. doi:10.1038/sj.jid.5700616.CrossRefPubMed

12.

Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137(6):978–85. doi:10.1309/AJCP9Q6OVLVSHTMY.CrossRefPubMed

13.

Yang X, Jiang X, Chen G, Xiao Y, Geng S, Kang C, et al. T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response. J Immunol. 2013;190(5):2068–79. doi:10.4049/jimmunol.1202661.CrossRefPubMed

14.

Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang L, et al. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS ONE. 2013;8(1):e53834. doi:10.1371/journal.pone.0053834.CrossRefPubMedPubMedCentral

15.

Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141–3. doi:10.1126/science.1148536.CrossRefPubMed

16.

Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, et al. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS ONE. 2013;8(12):e81799. doi:10.1371/journal.pone.0081799.CrossRefPubMedPubMedCentral

17.

Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Investig. 2012;122(4):1271–82. doi:10.1172/JCI59806.CrossRefPubMedPubMedCentral

18.

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187–94. doi:10.1084/jem.20100643.CrossRefPubMedPubMedCentral

19.

Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012;24(2):213–6. doi:10.1016/j.coi.2011.12.005.CrossRefPubMed

20.

Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832–42. doi:10.1038/ni.2376.CrossRefPubMedPubMedCentral

21.

Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536–41. doi:10.1038/415536a.CrossRefPubMed

22.

Ndhlovu LC, Lopez-Verges S, Barbour JD, Jones RB, Jha AR, Long BR, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012;119(16):3734–43. doi:10.1182/blood-2011-11-392951.CrossRefPubMedPubMedCentral

23.

Patel J, Bozeman EN, Selvaraj P. Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors. Immunotherapy. 2012;4(12):1795–8. doi:10.2217/imt.12.126.CrossRefPubMedPubMedCentral

24.

Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102–10. doi:10.1038/ni988.CrossRefPubMed

25.

Takamura S, Tsuji-Kawahara S, Yagita H, Akiba H, Sakamoto M, Chikaishi T, et al. Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol. 2010;184(9):4696–707. doi:10.4049/jimmunol.0903478.CrossRefPubMed

26.

Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE. 2012;7(2):e30676. doi:10.1371/journal.pone.0030676.CrossRefPubMedPubMedCentral

27.

Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, et al. TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(4):e23849.CrossRefPubMedPubMedCentral

28.

Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168(9):4272–6.CrossRefPubMed

29.

Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4+ CD25+ resting regulatory T cells from activated T cells. J Immunol. 2006;176(5):2808–16.CrossRefPubMed

30.

Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, et al. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res. 2013;19(19):5351–60. doi:10.1158/1078-0432.CCR-13-0035.CrossRefPubMedPubMedCentral

31.

Bu M, Shen Y, Seeger WL, An S, Qi R, Sanderson JA, et al. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression. Tumour Biol. 2016;37(3):3949–56. doi:10.1007/s13277-015-4237-x.CrossRefPubMed

32.

Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol. 2008;181(11):7660–9.CrossRefPubMed

33.

Simmons WJ, Koneru M, Mohindru M, Thomas R, Cutro S, Singh P, et al. Tim-3 + T-bet + tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms. J Immunol. 2005;174(3):1405–15.CrossRefPubMed

34.

Hafler DA, Kuchroo V. TIMs: central regulators of immune responses. J Exp Med. 2008;205(12):2699–701. doi:10.1084/jem.20082429.CrossRefPubMedPubMedCentral

35.

Gupta S, Thornley TB, Gao W, Larocca R, Turka LA, Kuchroo VK, et al. Allograft rejection is restrained by short-lived TIM-3+ PD-1+ Foxp3+ Tregs. J Clin Investig. 2012;122(7):2395–404.CrossRefPubMedPubMedCentral

36.

Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–88. doi:10.1146/annurev.immunol.021908.132603.CrossRefPubMed

37.

Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Investig. 2014;124(5):2246–59. doi:10.1172/JCI73639.CrossRefPubMedPubMedCentral

38.

Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–9.CrossRefPubMed

39.

Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682–7. doi:10.1038/nature04444.CrossRefPubMed

40.

Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501–10. doi:10.1182/blood-2010-10-310425.CrossRefPubMedPubMedCentral

41.

Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Can Res. 2012;72(4):887–96. doi:10.1158/0008-5472.CAN-11-2637.CrossRef

42.

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175–86. doi:10.1084/jem.20100637.CrossRefPubMedPubMedCentral

43.

Liu JF, Ma SR, Mao L, Bu LL, Yu GT, Li YC, et al. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer. Mol Oncol. 2017;11(2):235–47. doi:10.1002/1878-0261.12029.CrossRefPubMed

44.

Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol. 2013;32(11):648–53.CrossRefPubMed

45.

Han S, Feng S, Xu L, Shi W, Wang X, Wang H, et al. Tim-3 on peripheral CD4(+) and CD8(+) T cells is involved in the development of glioma. DNA Cell Biol. 2014;33(4):245–50. doi:10.1089/dna.2013.2306.CrossRefPubMed

46.

Tong D, Zhou Y, Chen W, Deng Y, Li L, Jia Z, et al. T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer. Mol Biol Rep. 2012;39(11):9941–6. doi:10.1007/s11033-012-1862-y.CrossRefPubMed

47.

Fang L, Lowther DE, Meizlish ML, Anderson RC, Bruce JN, Devine L, et al. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro-oncology. 2013;15(11):1479–90. doi:10.1093/neuonc/not110.CrossRefPubMedPubMedCentral

48.

Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol. 2013;32(11):648–53.CrossRefPubMed

49.

Piao YR, Jin ZH, Yuan KC, Jin XS. Analysis of Tim-3 as a therapeutic target in prostate cancer. Tumour Biol. 2014;35(11):11409–14. doi:10.1007/s13277-014-2464-1.CrossRefPubMedPubMedCentral

50.

Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol. 2006;24(5):762–8. doi:10.1200/JCO.2005.03.2813.CrossRefPubMed

51.

Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32(3):305–15.CrossRefPubMed

52.

Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med. 2013;11:215.CrossRefPubMedPubMedCentral

Title: Role of TIM-3 in ovarian cancer
Authors: Y. Xu
H. Zhang
Y. Huang
X. Rui
F. Zheng
Publication date: 01-09-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 9/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1656-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2017

Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer

Implementation of safeguards to improve patient safety in chemotherapy

Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery

Management and outcome of children with neuroendocrine tumors of the appendix in Spain: Is there room for improvement?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer